Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal

梯瓦制药与Canndoc公司达成战略分销协议,涉足医用大麻市场

2019-09-17 10:30:00 Benzinga

本文共1196个字,阅读需3分钟

Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential. Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has taken a giant leap of faith in this direction. The Canna-Pharma Tie-up Teva's subsidiary Salomon, Levin, Elstein, better known as S.L.E., and Canndoc, a subsidiary of InterCure Ltd (OTC: IRCLF), struck a strategic distribution agreement, under which Teva's subsidiary will distribute Cannadoc's GMP products to pharma clients, which include hospitals, health maintenance organization and all pharmacies in Israel. The agreement also allows S.L.E. to provide logistics capability to export Cannadoc's products to countries where sale and distribution of medical cannabis products are legalized. The distribution agreement will run for a three-year, and carries the option for automatic extension for two years each. S.L.E. has an Israeli Health Ministry license for GDP distribution. Meanwhile, Cannadoc is among the first licensed producers, with its GMP-approved medical cannabis prescription products sold in pharmacies. Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago. A Win-Win Scenario For Cannadoc, the Teva deal provides the leeway to distribute GMP products to its patients within the S.L.E. pharmacy network throughout Israel, while it can also leverage the latter's logistical capabilities for exporting its products. "Through its S.L.E. partnership, Canndoc has aligned itself with one of the most prominent pharmaceutical companies in the world, for the distribution of cannabis-based medical treatments to countries that recognize the value of these medicines for people in need," said Canndoc Chairman Ehud Barak. Teva shares have been on an extended downtrend, as the company is besieged by multiple issues, including dropping revenues, especially of its multiple sclerosis drug Capaxone, margin squeeze stemming from slumping generic prices and liabilities associated with price gouging allegations. Big Pharma Players Take Note Aside of the Teva deal, there has been increasing interest among big pharma companies to gain a foothold or at least a toehold in the burgeoning medical cannabis industry. GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) has an FDA-approved CBD drug for epilepsy in Epidiolex. By June 2018, there were about 400 clinical trials, both active and completed, involving cannabis world over, according to Visual Capitalist. Medical cannabis sales could touch $5.9 billion in 2019, according to the report. It has the potential to poach about $4 billion in sales from the pharma industry annually. Some of the other high profile pharma companies working on medical cannabis drugs include Sanofi SA (NASDAQ: SNY), Pfizer Inc. (NYSE: PFE), GlaxoSmithKline plc (NYSE: GSK) and Inc (NYSE: ABBV).
坎纳比斯公司一直在狂热地建立伙伴关系,彼此,饮料公司和生物制药公司,以利用市场的巨大潜力。 位于以色列的梯瓦(Teva)制药工业有限公司( NYSE : TEVA )在这方面已经取得了巨大的飞跃。 Canna-Pharma 联盟 Teva 公司的子公司 Salomon 、 Levin 、 Elstein 、更知名的 S.L.E .和 InterCure Ltd (非处方药(OTC): IRCLF )的子公司 Canndoc 达成了战略分销协议,根据该协议,梯瓦(Teva)公司的子公司将向包括以色列医院、健康维护组织和所有药店在内的医药客户分销 Cannadaloc 的 GMP 产品。 该协议还允许 S.L.E .提供物流能力,将卡纳达克的产品出口到销售和分销医用大麻产品合法化的国家。 经销协议有效期为三年,可选择自动延期两年。S.L.E .拥有以色列卫生部的国内生产总值分配许可证。 与此同时,卡纳达克是第一批获得许可的生产商之一,其 GMP 批准的医用大麻处方产品在药店销售。 点击这里了解更多关于即将于10月22-23日在芝加哥举行的 Benzinga Cannabis 资本会议的信息。 双赢情景 对于坎纳多克而言,梯瓦(Teva)交易为其在整个以色列的 S.L.E .药房网络内向患者分销 GMP 产品提供了回旋余地,同时也可以利用后者的物流能力出口其产品。 Canndoc 主席 Ehud Barak 说:“通过与 S.L.E .的合作, Canndoc 已经与世界上最著名的制药公司之一结盟,向那些认识到这些药物对需要帮助的人的价值的国家分配基于大麻的医疗。 梯瓦(Teva)股价一直处于持续下跌的趋势,因为该公司受到多个问题的困扰,包括收入下滑,尤其是其多发性硬化症药物卡泊松( Capxone ),因仿制药价格下跌造成的利润挤压,以及与价格欺诈指控相关的负债。 大型制药企业请注意 除了梯瓦(Teva)交易外,大型制药公司对在新兴的医用大麻行业站稳脚跟或至少站稳脚跟的兴趣也越来越浓厚。 GW Pharmaceuticals PLC-ADR ( NASDAQ : GWPH )拥有 FDA 批准的 Epidiolex 癫痫 CBD 药物。根据 VisualCapitalist 的数据,截至2018年6月,全球约有400项临床试验正在进行中并已完成,涉及大麻。 报告称,2019年医用大麻销售额可能达到59亿美元。它有可能每年从制药业获得约40亿美元的销售额。 从事医用大麻药品的其他一些知名制药公司包括赛诺菲( Sanofi )公司( NASDAQ : SNY )、辉瑞公司( Pfizer Inc .)( NYSE : PFE )、葛兰素史克(GlaxoSmithKline)公司( NYSE :葛兰素史克(GSK))和 Inc ( NYSE : ABBV )。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文